How have TTOO shares performed in 2024?

T2 Biosystems' stock was trading at $6.28 at the start of the year. Since then, TTOO stock has decreased by 53.3% and is now trading at $2.93. View the best growth stocks for 2024 here .

Are investors shorting T2 Biosystems?

T2 Biosystems saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average daily trading volume, of 255,400 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the company's stock are short sold. View T2 Biosystems' Short Interest .

When is T2 Biosystems' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024. View our TTOO earnings forecast .

How were T2 Biosystems' earnings last quarter?

T2 Biosystems, Inc. (NASDAQ:TTOO) announced its earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) EPS for the quarter, meeting analysts' consensus estimates of ($400.00). The medical equipment provider had revenue of $7.43 million for the quarter. During the same period in the prior year, the firm posted ($400.00) EPS.

When did T2 Biosystems' stock split?

T2 Biosystems's stock reverse split on the morning of Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has T2 Biosystems issued on next quarter's earnings?

T2 Biosystems updated its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million.

What is John McDonough's approval rating as T2 Biosystems' CEO?

36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com . John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of T2 Biosystems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE) , Inovio Pharmaceuticals (INO) , VBI Vaccines (VBIV) , Tonix Pharmaceuticals (TNXP) , OPKO Health (OPK) , SCYNEXIS (SCYX) , Biocept (BIOC) , Heat Biologics (HTBX) , NVIDIA (NVDA) and Vaxart (VXRT) .

How do I buy shares of T2 Biosystems?

Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:TTOO

T2 Biosystems (TTOO) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free TTOO Stock Alerts

$2.99

+0.05 (+1.70%)

(As of 04/18/2024 ET)

Compare

Today's Range: $2.88
▼
$3.00
50-Day Range: $2.79
▼
$6.49
52-Week Range: $2.70
▼
$70.00

Volume: 106,620 shs
Average Volume: 251,914 shs
Market Capitalization: $16.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get T2 Biosystems alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About T2 Biosystems Stock (NASDAQ:TTOO)

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

TTOO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

TTOO Stock News Headlines

April 15, 2024 | americanbankingnews.com

T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update

April 13, 2024 | investing.com

T2 Biosystems converts $15M loan to equity, aims for Nasdaq compliance

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | finanznachrichten.de

T2 Biosystems, Inc.: T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity

April 11, 2024 | globenewswire.com

T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity

March 28, 2024 | finanznachrichten.de

T2 Biosystems, Inc.: T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

March 28, 2024 | globenewswire.com

T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.

March 20, 2024 | finanznachrichten.de

T2 Biosystems, Inc.: T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 20, 2024 | markets.businessinsider.com

T2 Biosystems Targets Commercial Launch Of T2Lyme Panel In Q3 - Quick Facts

March 20, 2024 | globenewswire.com

T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates

March 19, 2024 | globenewswire.com

T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates

March 18, 2024 | globenewswire.com

T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel

March 12, 2024 | investorplace.com

TTOO Stock: T2 Biosystems Has Until May 20 to Regain Nasdaq Compliance

March 12, 2024 | finanznachrichten.de

T2 Biosystems, Inc.: T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

March 12, 2024 | globenewswire.com

T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement

February 16, 2024 | money.usnews.com

T2 Biosystems Inc

February 16, 2024 | finance.yahoo.com

T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2023 Earnings Call Transcript

February 16, 2024 | finanznachrichten.de

T2 Biosystems, Inc.: T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

February 16, 2024 | finance.yahoo.com

Q4 2023 T2 Biosystems Inc Earnings Call

February 15, 2024 | finance.yahoo.com

T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

February 15, 2024 | finance.yahoo.com

T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity

February 15, 2024 | finance.yahoo.com

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | globenewswire.com

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | globenewswire.com

T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity

February 15, 2024 | globenewswire.com

T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia

February 14, 2024 | benzinga.com

Earnings Preview For T2 Biosystems

See More Headlines

Receive TTOO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/28/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: NASDAQ:TTOO
CUSIP: N/A
CIK: 1492674
Web: www.t2biosystems.com
Phone: (781) 761-4646
Fax: 781-357-3080
Employees: 113
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-50,080,000.00
Net Margins: -696.19%
Pretax Margin: -696.19%
Return on Equity: N/A
Return on Assets: -129.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.45
Quick Ratio: 0.36

Sales & Book Value

Annual Sales: $7.19 million
Price / Sales: 2.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($6.91) per share
Price / Book: -0.43

Miscellaneous

Outstanding Shares: 5,510,000
Free Float: 5,506,000
Market Cap: $16.31 million
Optionable: Optionable
Beta: 0.11

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. John J. Sperzel III (Age 61)
B.Sc., President, CEO & Chairman
Comp: $865.5k
Mr. John M. Sprague CPA (Age 66)
Chief Financial Officer
Comp: $581k
Mr. Michael Terrence Gibbs Esq. (Age 53)
Senior VP, General Counsel & Company Secretary
Comp: $622.6k
Ms. Kelley J. Morgan (Age 48)
Chief People Officer
Mr. Brett A. Giffin (Age 65)
Chief Commercial Officer
Dr. Roger Smith Ph.D. (Age 59)
Senior Vice President of Science Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

TTOO Stock Analysis - Frequently Asked Questions

How have TTOO shares performed in 2024?: T2 Biosystems' stock was trading at $6.28 at the start of the year. Since then, TTOO stock has decreased by 53.3% and is now trading at $2.93.
View the best growth stocks for 2024 here.
Are investors shorting T2 Biosystems?: T2 Biosystems saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 396,900 shares, an increase of 34.4% from the March 15th total of 295,400 shares. Based on an average daily trading volume, of 255,400 shares, the days-to-cover ratio is currently 1.6 days. Approximately 11.6% of the company's stock are short sold.
View T2 Biosystems' Short Interest.
When is T2 Biosystems' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 28th 2024.
View our TTOO earnings forecast.
How were T2 Biosystems' earnings last quarter?: T2 Biosystems, Inc. (NASDAQ:TTOO) announced its earnings results on Thursday, November, 4th. The medical equipment provider reported ($400.00) EPS for the quarter, meeting analysts' consensus estimates of ($400.00). The medical equipment provider had revenue of $7.43 million for the quarter. During the same period in the prior year, the firm posted ($400.00) EPS.
When did T2 Biosystems' stock split?: T2 Biosystems's stock reverse split on the morning of Friday, October 13th 2023. The 1-100 reverse split was announced on Friday, October 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, October 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has T2 Biosystems issued on next quarter's earnings?: T2 Biosystems updated its fourth quarter 2023 earnings guidance on Friday, February, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.7 million-$1.7 million, compared to the consensus revenue estimate of $2.4 million.
What is John McDonough's approval rating as T2 Biosystems' CEO?: 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of T2 Biosystems own?: Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT).
How do I buy shares of T2 Biosystems?: Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TTOO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

T2 Biosystems (TTOO) Stock Price, News & Analysis

About T2 Biosystems Stock (NASDAQ:TTOO)

TTOO Stock Price History

TTOO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

TTOO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info